You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 14, 2024

BROMOCRIPTINE MESYLATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Bromocriptine Mesylate, and when can generic versions of Bromocriptine Mesylate launch?

Bromocriptine Mesylate is a drug marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Aurobindo Pharma Usa, Padagis Us, and Sandoz. and is included in six NDAs.

The generic ingredient in BROMOCRIPTINE MESYLATE is bromocriptine mesylate. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Bromocriptine Mesylate

A generic version of BROMOCRIPTINE MESYLATE was approved as bromocriptine mesylate by SANDOZ on January 13th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BROMOCRIPTINE MESYLATE?
  • What are the global sales for BROMOCRIPTINE MESYLATE?
  • What is Average Wholesale Price for BROMOCRIPTINE MESYLATE?
Summary for BROMOCRIPTINE MESYLATE
Drug patent expirations by year for BROMOCRIPTINE MESYLATE
Drug Prices for BROMOCRIPTINE MESYLATE

See drug prices for BROMOCRIPTINE MESYLATE

Recent Clinical Trials for BROMOCRIPTINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Case Western Reserve UniversityPhase 1/Phase 2
Andrew Moshfeghi, MD, MBAPhase 1/Phase 2
VeroSciencePhase 1

See all BROMOCRIPTINE MESYLATE clinical trials

Pharmacology for BROMOCRIPTINE MESYLATE
Drug ClassErgot Derivative
Medical Subject Heading (MeSH) Categories for BROMOCRIPTINE MESYLATE

US Patents and Regulatory Information for BROMOCRIPTINE MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lek Pharm BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 075100-001 Dec 10, 1998 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Usa BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 076962-001 Sep 24, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 077226-001 Apr 4, 2005 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms Usa Inc BROMOCRIPTINE MESYLATE bromocriptine mesylate CAPSULE;ORAL 078899-001 Jul 30, 2008 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 074631-001 Jan 13, 1998 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Padagis Us BROMOCRIPTINE MESYLATE bromocriptine mesylate TABLET;ORAL 077646-001 Oct 1, 2008 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.